Allogene Therapeutics (ALLO) Enterprise Value (2018 - 2026)

Allogene Therapeutics has reported Enterprise Value for 9 years, with the latest figure at -$261.6 million in Q1 2026.

• Quarterly Enterprise Value rose 6.57% year-over-year to -$261.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$261.6 million (up 6.57% YoY) and the FY2025 annual result came in at -$250.2 million, up 14.45% from the prior year.
• Enterprise Value eased to -$261.6 million in Q1 2026 per ALLO's latest filing, from -$250.2 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$250.2 million in Q4 2025 and troughed at -$552.2 million in Q3 2022.
• A 5-year average of -$384.7 million and a median of -$435.5 million in 2024 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2022 and 2024: Enterprise Value fell 28.95% in 2022, then surged 38.93% in 2024.
• Over 5 years, Enterprise Value stood at -$467.2 million in 2022, then advanced by 4.94% to -$444.1 million in 2023, then jumped by 34.14% to -$292.5 million in 2024, then climbed by 14.45% to -$250.2 million in 2025, then declined by 4.56% to -$261.6 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$261.6 million, -$250.2 million, and -$252.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.